- Title
- Effect of fractional exhaled nitric oxide (FENO)-based asthma management during pregnancy versus usual care on infant development, temperament, sensory function and autism signs
- Creator
- Whalen, Olivia M.; Campbell, Linda E.; Murphy, Vanessa E.; Lane, Alison E.; Karayanidis, Frini; Mallise, Carly A.; Woolard, Alix J.; Holliday, Elizabeth G.; Mattes, Joerg; Collison, Adam; Gibson, Peter G.
- Relation
- European Journal of Pediatrics Vol. 183, Issue 8, p. 3199-3210
- Publisher Link
- http://dx.doi.org/10.1007/s00431-024-05578-4
- Publisher
- Springer
- Resource Type
- journal article
- Date
- 2024
- Description
- Asthma during pregnancy is associated with a range of adverse perinatal outcomes. It is also linked to increased rates of neurodevelopmental conditions in the offspring. We aimed to assess whether fractional exhaled nitric oxide (FENO)-based asthma management during pregnancy improves child developmental and behavioural outcomes compared to usual care. The Breathing for Life Trial was a randomised controlled trial that compared FENO-based asthma management during pregnancy to usual care. Participants were invited to the developmental follow-up, the Breathing for Life Trial – Infant Development study, which followed up infants at 6 weeks, 6 months and 12 months. The primary outcomes were measured in infants at 12 months using the Bayley-III: Cognitive, Language and Motor composite scores. Secondary outcomes included Bayley-III social-emotional and adaptive behaviour scores, autism likelihood and sensory and temperament outcomes. The exposure of interest was the randomised intervention group. Two hundred and twenty-two infants and their 217 participating mothers were recruited to the follow-up; 107 mothers were in the intervention group and 113 were in the control group. There was no evidence of an intervention effect for the primary outcomes: Bayley-III cognitive (mean = 108.9 control, 108.5 intervention, p = 0.93), language (mean = 95.9 control, 95.6 intervention, p = 0.87) and motor composite scores (mean = 97.2 control, 97.9 intervention, p = 0.25). Mean scores for secondary outcomes were also similar among infants born to control and FENO group mothers, with few results reaching p < 0.05. Conclusion: In this sample, FENO-guided asthma treatment during pregnancy did not improve infant developmental outcomes in the first year of life. Trial registration: ClinicalTrials.gov Identifier: ACTRN12613000202763.
- Subject
- asthma; pregnancy; postpartum; FENO; child development; temperament; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1510486
- Identifier
- uon:56413
- Identifier
- ISSN:0340-6199
- Language
- eng
- Reviewed
- Hits: 651
- Visitors: 644
- Downloads: 0